Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 8/2012

01.08.2012 | Short Communication

A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma

verfasst von: J. B. Maurice, R. Troke, Z. Win, R. Ramachandran, A. Al-Nahhas, M. Naji, W. Dhillo, K. Meeran, A. P. Goldstone, N. M. Martin, J. F. Todd, F. Palazzo, T. Tan

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare the sensitivity of 123I-metaiodobenzylguanidine (MIBG) SPECT and 68Ga-DOTATATE PET/CT in detecting phaeochromocytomas (PCC) and paragangliomas (PGL) in the initial diagnosis and follow-up of patients with PCC and PGL disease.

Methods

Retrospective analysis of 15 patients with PCC/PGL who had contemporaneous 123I-MIBG and 68Ga-DOTATATE imaging.

Results

Of the 15 patients in the series, 8 were concordant with both modalities picking up clinically significant lesions. There were no patients in whom both modalities failed to pick up clinically significant lesions. There was discordance in seven patients: 5 had positive 68Ga-DOTATATE and negative 123I-MIBG, and 2 (12 and 14) had negative 68Ga-DOTATATE and positive 123I-MIBG. Utilizing 123I-MIBG as the gold standard, 68Ga-DOTATATE had a sensitivity of 80 % and a positive predictive value of 62 %. The greatest discordance was in head and neck lesions, with the lesions in 4 patients being picked up by 68Ga-DOTATATE and missed by 123I-MIBG. On a per-lesion analysis, cross-sectional (CT and MRI) and 68Ga-DOTATATE was superior to 123I-MIBG in detecting lesions in all anatomical locations, and particularly bony lesions.

Conclusion

First, 68Ga-DOTATATE should be considered as a first-line investigation in patients at high risk of PGL and metastatic disease, such as in the screening of carriers for mutations associated with familial PGL syndromes. Second, if 123I-MIBG does not detect lesions in patients with a high pretest probability of PCC or PGL, 68Ga-DOTATATE should be considered as the next investigation. Third, 68Ga-DOTATATE hould be considered in preference to 123I-MIBG in patients in whom metastatic spread, particularly to the bone, is suspected.
Literatur
1.
Zurück zum Zitat Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007;3(2):92–102. doi:10.1038/ncpendmet0396.PubMedCrossRef Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007;3(2):92–102. doi:10.​1038/​ncpendmet0396.PubMedCrossRef
3.
Zurück zum Zitat Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, Steinke R, et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab. 2003;88(11):5150–7.PubMedCrossRef Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, Steinke R, et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab. 2003;88(11):5150–7.PubMedCrossRef
4.
Zurück zum Zitat Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49(10):1613–9. doi:10.2967/jnumed.108.052373.PubMedCrossRef Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I, et al. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49(10):1613–9. doi:10.​2967/​jnumed.​108.​052373.PubMedCrossRef
6.
Zurück zum Zitat Naswa N, Sharma P, Nazar AH, Agarwal KK, Kumar R, Ammini AC, et al. Prospective evaluation of (68)Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study. Eur Radiol. 2012;22(3):710–9. doi:10.1007/s00330-011-2289-x.PubMedCrossRef Naswa N, Sharma P, Nazar AH, Agarwal KK, Kumar R, Ammini AC, et al. Prospective evaluation of (68)Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study. Eur Radiol. 2012;22(3):710–9. doi:10.​1007/​s00330-011-2289-x.PubMedCrossRef
7.
Zurück zum Zitat Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95(6):2800–10. doi:10.1210/jc.2009-2352.PubMedCrossRef Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95(6):2800–10. doi:10.​1210/​jc.​2009-2352.PubMedCrossRef
8.
Zurück zum Zitat van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86(2):685–93.PubMedCrossRef van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86(2):685–93.PubMedCrossRef
9.
Zurück zum Zitat Bhatia KS, Ismail MM, Sahdev A, Rockall AG, Hogarth K, Canizales A, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol. 2008;69(2):181–8. doi:10.1111/j.1365-2265.2008.03256.x.CrossRef Bhatia KS, Ismail MM, Sahdev A, Rockall AG, Hogarth K, Canizales A, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol. 2008;69(2):181–8. doi:10.​1111/​j.​1365-2265.​2008.​03256.​x.CrossRef
10.
Zurück zum Zitat Charrier N, Deveze A, Fakhry N, Sebag F, Morange I, Gaborit B, et al. Comparison of [111In]-pentetreotide-SPECT and [18F]-FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol. 2011;74(1):21–9. doi:10.1111/j.1365-2265.2010.03893.x.CrossRef Charrier N, Deveze A, Fakhry N, Sebag F, Morange I, Gaborit B, et al. Comparison of [111In]-pentetreotide-SPECT and [18F]-FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities. Clin Endocrinol. 2011;74(1):21–9. doi:10.​1111/​j.​1365-2265.​2010.​03893.​x.CrossRef
Metadaten
Titel
A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma
verfasst von
J. B. Maurice
R. Troke
Z. Win
R. Ramachandran
A. Al-Nahhas
M. Naji
W. Dhillo
K. Meeran
A. P. Goldstone
N. M. Martin
J. F. Todd
F. Palazzo
T. Tan
Publikationsdatum
01.08.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2012
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-012-2119-7

Weitere Artikel der Ausgabe 8/2012

European Journal of Nuclear Medicine and Molecular Imaging 8/2012 Zur Ausgabe